CAMBRIDGE, England--(BUSINESS WIRE)--Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced the appointment of Dr. Alex Dickinson to its Board of Directors as a Non-Executive Director (NED).

英国剑桥——（商业新闻短讯）——Sphere Fluidics是单细胞分析和分离创新微流体解决方案的领先供应商，今天宣布任命Alex Dickinson博士为董事会非执行董事（NED）。

Alex is a seasoned executive bringing substantial experience from the intersection of healthcare, life sciences, and information technology to Sphere Fluidics’ leadership team. He joins the Board as part of a series of significant senior appointments to drive forward the Company’s global commercial expansion strategy, leveraging Alex’s extensive entrepreneurial and technical expertise to augment increased R&D efforts in areas of cutting-edge technological advancement..

Alex是一位经验丰富的高管，为Sphere Fluidics的领导团队带来了医疗保健、生命科学和信息技术交叉领域的丰富经验。他加入董事会是一系列重要高级任命的一部分，旨在推动公司的全球商业扩张战略，利用Alex广泛的创业和技术专业知识，在尖端技术进步领域加大研发力度。。

Dale Levitzke, CEO, Sphere Fluidics, commented: “It is exciting to be working with Alex again. His caliber within the industry and extensive connections are exceptional, not only bringing deep insights on life science tools in the growing cell and gene therapy space, but also how we can leverage new advances in AI to enhance our offerings.

Sphere Fluidics首席执行官戴尔·莱维茨克（Dale Levitzke）评论道：“再次与亚历克斯（Alex）合作令人兴奋。他在行业内的才干和广泛的联系是非凡的，不仅为不断增长的细胞和基因治疗领域的生命科学工具带来了深刻的见解，而且我们还可以如何利用人工智能的新进展来增强我们的产品。

Alex’s proven success in steering companies with cutting-edge technology platforms will be invaluable to the Company’s continued growth, particularly as we focus on expansion in the US.”.

Alex在使用尖端技术平台指导公司方面取得的成功将对公司的持续增长至关重要，尤其是当我们专注于在美国扩张时。”。

From 2010 to 2017, Alex was Senior Vice President of Strategic Initiatives at Illumina, during which time revenues increased from £1 billion to £3 billion. In this position, he founded and led development of the cloud-based BaseSpace platform, which remains the Company’s core bioinformatics offering, and ran its global population sequencing healthcare programs.

。在这个职位上，他创建并领导了基于云的BaseSpace平台的开发，该平台仍然是该公司的核心生物信息学产品，并负责其全球人口测序医疗保健计划。

Alex joined Illumina through the acquisition of Helixis, which he co-founded with Nobel laureate David Baltimore and led as CEO. He was also the Founder and CEO of Luxtera, a leading supercomputer chip company acquired by Cisco Systems in 2019..

亚历克斯通过收购Helixis加入了Illumina，他与诺贝尔奖获得者大卫·巴尔的摩共同创立了Helixis，并担任首席执行官。他还是Luxtera的创始人兼首席执行官，Luxtera是一家领先的超级计算机芯片公司，于2019年被Cisco Systems收购。。

In addition to his new role at Sphere Fluidics, Alex is currently a Board Member of Gencove, pioneers of low-pass whole genome sequencing imputation and analysis, Co-Founder and Board Member of ChromaCode, innovators in genomics multiplexing technology, and Co-Founder and Chairman of Ryght.ai, healthcare technology developers leveraging generative AI and optimizing large language models (LLMs) to maximize productivity in biopharma discovery and clinical trials.

。

Previously, he was a Board Member at NASDAQ-listed Clinical Research Organization, PRA Health Sciences, until its acquisition by ICON plc in 2021..

此前，他是纳斯达克上市的临床研究组织PRA Health Sciences的董事会成员，直到2021年被ICON plc收购。。

Dr. Alex Dickinson, Non-Executive Board Director, Sphere Fluidics, said: “What really excites me about joining Sphere Fluidics is the talent across the team and the capabilities of its microfluidic technology, with many cutting-edge developments already in the pipeline. Having worked closely with Dale at Illumina and Helixis, I am looking forward to joining him again to drive success at this pivotal stage in the Company’s development.”.

Sphere Fluidics非执行董事会董事Alex Dickinson博士表示：“加入Sphere Fluidics真正让我兴奋的是整个团队的人才及其微流体技术的能力，许多尖端的开发已经在进行中。与Illumina和Helixis的Dale密切合作后，我期待再次加入他，在公司发展的这个关键阶段取得成功。”。

He added: “There is a wealth of opportunities being created around the combination of life science technologies and emerging AI and machine-learning tools, such as LLMs. As one aspect of my new role, I am keen to explore how we can leverage these pioneering techniques alongside the platforms’ proven capabilities in data generation and analysis, opening new avenues for innovation and product development that are transformative for customers’ workflows.”.

他补充道：“围绕生命科学技术与新兴AI和机器学习工具（如LLM）的结合，正在创造大量机会。作为我新角色的一个方面，我渴望探索如何利用这些开创性技术以及平台在数据生成和分析方面经验证的能力，为创新和产品开发开辟新途径，从而改变客户的工作流程。”。